Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Merck KGaA
  6. Summary
    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
Delayed Quote. Delayed Xetra - 10/22 11:35:27 am
202.4 EUR   -0.49%
10/22MERCK : Moody's Raises Merck KGaA's Rating to A3 on Improved Business Profile
MT
10/21MARKETMIND : Back to the blues
RE
10/20MERCK KGAA : Barclays takes a positive view
MD
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
193.1(c) 195.05(c) 198.05(c) 203.4(c) 202.4(c) Last
197 815 238 589 332 196 391 657 256 402 Volume
+0.39% +1.01% +1.54% +2.70% -0.49% Change
More quotes
Estimated financial data (e)
Sales 2021 19 375 M 22 558 M 22 558 M
Net income 2021 2 765 M 3 219 M 3 219 M
Net Debt 2021 8 932 M 10 400 M 10 400 M
P/E ratio 2021 31,5x
Yield 2021 0,76%
Sales 2022 20 660 M 24 054 M 24 054 M
Net income 2022 3 013 M 3 508 M 3 508 M
Net Debt 2022 6 912 M 8 048 M 8 048 M
P/E ratio 2022 29,0x
Yield 2022 0,83%
Capitalization 87 999 M 102 B 102 B
EV / Sales 2021 5,00x
EV / Sales 2022 4,59x
Nbr of Employees 58 408
Free-Float 29,7%
More Financials
Company
Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Performance Materials. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical devices. The... 
Sector
Pharmaceuticals
Calendar
11/11 | 01:00amEarnings Release
More about the company
Ratings of Merck KGaA
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about MERCK KGAA
10/22MERCK : Moody's Raises Merck KGaA's Rating to A3 on Improved Business Profile
MT
10/21MARKETMIND : Back to the blues
RE
10/20MERCK KGAA : Barclays takes a positive view
MD
10/20CytoReason Collaborates with Merck KGaA on Cancer Immunotherapy Drug
CI
10/20MARKETMIND : Margin pressures
RE
10/19MARKETMIND : Fast and furious
RE
10/14MERCK KGAA : Release according to Article 40, Section 1 of the WpHG [the German Securities..
EQ
10/14MERCK : EMD Serono, Inc. - New Real-World MAVENCLAD Data Show Sustained Effectiveness and ..
AQ
10/13Merck KGaA's Multiple Sclerosis Treatment Drug Shows Improved Quality Of Life In Study
MT
10/13MERCK KGAA : JP Morgan reaffirms its Buy rating
MD
10/12MERCK : Opens Second Facility In California, US, With $115 Million Investment
MT
10/12MERCK KGAA : Bernstein reiterates its Neutral rating
MD
10/12MERCK : MilliporeSigma Announces Completion of New Viral Vector Contract Development Manuf..
AQ
10/07MERCK KGAA : Gets a Neutral rating from NorldLB
MD
10/06MARKETMIND : Hunker down, it's going to be one of those days
RE
More news
News in other languages on MERCK KGAA
10/22Moody's relève la note de Merck KGaA à A3 en raison de l'amélioration de son profil com..
10/21Moody's stuft Merck KGaA auf A3 hoch; Ausblick stabil
10/21MARKETMIND : Retour au blues
10/13Le médicament de Merck KGaA pour le traitement de la sclérose en plaques montre une amé..
10/13La energía se dispara, las acciones no tanto
More news
Analyst Recommendations on MERCK KGAA
More recommendations
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | MarketScreener
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 202,40 €
Average target price 200,03 €
Spread / Average Target -1,17%
EPS Revisions
Managers and Directors
Belén Garijo López Chairman-Executive Board & CEO
Marcus Kuhnert Chief Financial Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Maria Rivas Chief Medical Officer & Senior Vice President
Laura Matz Chief Science & Technology Officer
Sector and Competitors